temozolomide has been researched along with Mucositis in 3 studies
Mucositis: An INFLAMMATION of the MUCOSA with burning or tingling sensation. It is characterized by atrophy of the squamous EPITHELIUM, vascular damage, inflammatory infiltration, and ulceration. It usually occurs at the mucous lining of the MOUTH, the GASTROINTESTINAL TRACT or the airway due to chemical irritations, CHEMOTHERAPY, or radiation therapy (RADIOTHERAPY).
| Excerpt | Relevance | Reference |
|---|---|---|
| " Further clinical investigations aimed at elucidating the veliparib exposure-efficacy/safety relationship and optimizing dosing recommendations for maximizing benefit-risk in patients with advanced myeloid malignancies should study veliparib doses ranging up to 120 mg in combination with temozolomide." | 2.90 | Population pharmacokinetics and exposure-response assessment of veliparib co-administered with temozolomide in patients with myeloid leukemias. ( Beumer, JH; Chen, A; Gobburu, J; Gojo, I; Gopalakrishnan, M; Greer, JM; Karp, JE; Kiesel, BF; Mehrotra, S; Piekarz, R; Rudek, MA; Singh, R, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, Z | 1 |
| Zhou, Y | 1 |
| Luo, A | 1 |
| Heng, X | 1 |
| Liu, J | 1 |
| Wang, H | 1 |
| Chu, W | 1 |
| DeFilipp, Z | 1 |
| Li, S | 1 |
| El-Jawahri, A | 1 |
| Armand, P | 1 |
| Nayak, L | 1 |
| Wang, N | 1 |
| Batchelor, TT | 1 |
| Chen, YB | 1 |
| Singh, R | 1 |
| Mehrotra, S | 1 |
| Gopalakrishnan, M | 1 |
| Gojo, I | 1 |
| Karp, JE | 1 |
| Greer, JM | 1 |
| Chen, A | 1 |
| Piekarz, R | 1 |
| Kiesel, BF | 1 |
| Gobburu, J | 1 |
| Rudek, MA | 1 |
| Beumer, JH | 1 |
1 trial available for temozolomide and Mucositis
| Article | Year |
|---|---|
Population pharmacokinetics and exposure-response assessment of veliparib co-administered with temozolomide in patients with myeloid leukemias.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemother | 2019 |
2 other studies available for temozolomide and Mucositis
| Article | Year |
|---|---|
Lactobacillus salivarius CPU-01 Ameliorates Temozolomide-Induced Intestinal Mucositis by Modulating Gut Microbiota, Maintaining Intestinal Barrier, and Blocking Pro-inflammatory Cytokines.
Topics: Animals; Antineoplastic Agents; Cytokines; Gastrointestinal Microbiome; Intestinal Mucosa; Ligilacto | 2023 |
High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for patients with primary central nervous system lymphoma in first complete remission.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Busulfan; Central | 2017 |